Andrew Cheng is President and Chief Executive Officer of Akero Therapeutics, Inc. (AKRO). The company reported total compensation of $10,465,855 for fiscal year 2024.
| Salary | $686,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,879,155 |
| Option awards | $6,489,100 |
| Non-equity incentive plan | $411,600 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $10,465,855 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Akero Therapeutics, Inc. filed April 28, 2025, accession 0000950170-25-058964.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | President and Chief Executive Officer | $686,000 | $0 | $2,879,155 | $6,489,100 | $411,600 | $0 | $0 | $10,465,855 |
| FY2023 | President and Chief Executive Officer | $660,000 | $0 | $1,818,920 | $5,979,787 | $376,200 | $0 | $0 | $8,834,907 |
| FY2022 | President and Chief Executive Officer | $624,000 | $0 | $2,248,475 | $6,973,168 | $600,600 | $0 | $0 | $10,446,243 |
Totals as disclosed in each year's own compensation disclosure for Akero Therapeutics, Inc..
| Peer-group chief executive median | $7,973,839 |
|---|---|
| Difference from that median | $2,492,016 |
| Percentile within the disclosed peer group | 71st |
| Peers with a disclosed figure | 14 |
Medians and percentiles are computed across the peer group Akero Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Andrew Cheng this page | President and Chief Executive Officer | $10,465,855 |
| Scott Gangloff | Chief Technology Officer | $6,112,056 |
| William White | Chief Financial Officer | $3,067,674 |
| Catriona Yale | Chief Development Officer | $3,044,474 |
| Jonathan Young | Chief Operating Officer | $3,038,674 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Akero Therapeutics, Inc. compensation brief.
Andrew Cheng's compensation sits inside Akero Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.